Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: bruker.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2026 | Peer Perform | Wolfe Research | |
| 12/10/2025 | $60.00 | Peer Perform → Outperform | Wolfe Research |
| 12/9/2025 | $40.00 | Sell | Goldman |
| 11/20/2025 | $60.00 | Buy | Rothschild & Co Redburn |
| 5/22/2025 | $40.00 | Buy → Neutral | Citigroup |
| 12/19/2024 | $72.00 | Buy | Guggenheim |
| 12/10/2024 | $66.00 | Neutral | UBS |
| 12/5/2024 | $60.00 | Sell → Neutral | Goldman |
| 10/15/2024 | $75.00 | Overweight | Barclays |
| 9/30/2024 | Outperform → Peer Perform | Wolfe Research |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
3 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
SD - BRUKER CORP (0001109354) (Filer)
8-K/A - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
SCHEDULE 13G/A - BRUKER CORP (0001109354) (Subject)
10-Q - BRUKER CORP (0001109354) (Filer)
SCHEDULE 13G/A - BRUKER CORP (0001109354) (Subject)
8-K - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
DEFA14A - BRUKER CORP (0001109354) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wolfe Research resumed coverage of Bruker with a rating of Peer Perform
Wolfe Research upgraded Bruker from Peer Perform to Outperform and set a new price target of $60.00
Goldman initiated coverage of Bruker with a rating of Sell and set a new price target of $40.00
Rothschild & Co Redburn initiated coverage of Bruker with a rating of Buy and set a new price target of $60.00
Citigroup downgraded Bruker from Buy to Neutral and set a new price target of $40.00
Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00
UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00
Goldman upgraded Bruker from Sell to Neutral and set a new price target of $60.00
Barclays initiated coverage of Bruker with a rating of Overweight and set a new price target of $75.00
Wolfe Research downgraded Bruker from Outperform to Peer Perform
Fastest customizable press release news feed in the world
At ASM Microbe 2026, Bruker Corporation's (NASDAQ:BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604057503/en/MALDI Biotyper® sirius CA System, delivering high‑throughput microbial identification to support efficient clinical laboratory workflows and improved diagnostic turnaround times During the ASM 2026 meeting, Bruker showcases the expa
At ASMS, Bruker Corporation (NASDAQ:BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative platform that combines Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), to unravel the complex molecular makeup of challenging fossil fuels and green energy materials. It accomplishes this with unparalleled mass resolution (>10M) and sub-parts-per-million mass accuracy, plus isotope fine structure identification-confirmation, which enables the most confident identification of molecular species in ultra-complex mixture
Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing Launch of eXtreme 10M resolution novel timsMRMS™ mass spectrometer for ultra-complex mixture analysis in energy industry and life-science research Breakthrough timsUltra™ AIP bottom-up proteomics performance: instrument improvements, new razor-PASEF™ methods and Spectronaut 21 software enable ID and LFQ beyond 10,000 proteins in cell lines and tissue, with >6,500 proteins at 500 SPD, and leading plasma proteomics performance with single-particle P2 enrichment Revolutionary timsOmni™ enables unmatched multi-stage, ultra-sensitive trapped Ex
World's highest-field MRI system provides leading disease biology research capabilities Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue microstructure, and localized metabolism and dynamics are critical. This press release features multimedia. View the full release here: https://www.b
Q1 2026 revenues of $823.4 million, up 2.7% year-over-year (yoy), down 4.4% organically Q1-26 GAAP diluted earnings per share (EPS) $0.02; non-GAAP diluted EPS $0.31 Q1-26 Bruker Scientific Instruments (BSI) bookings up high-single digits % organically yoy; BSI book-to-bill ratio above 1.0x for 3rd consecutive quarter Reconfirming previous FY2026 guidance: Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2% Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind Bruker Corporation (NASDAQ:BRKR) today announced financial results for the three months ended March 31, 2026. Frank H. Laukien, Bruker's President and C
Bruker Corporation (NASDAQ:BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026. The Company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q1 2026 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-4
Bruker Spatial Biology features new GeoMx-to-CellScape and CellScape-to-CosMx cross-platform workflows and first-of-its-kind 208-plex CellScape XR spatial proteomics datasets Bruker Corporation (NASDAQ:BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting. At AACR, Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417773444/en/PaintScape in sit
At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division ((Bruker Corporation, NASDAQ:BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius® system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO® automates the entire workflow - from patient sample to diagnostic result - e
MALDI Biotyper® (MBT): Launch of proprietary MBT Easy T® Kit for consistent sample transfer to MALDI target plates MALDI Biotyper®: Expansion of reference libraries to more than 5,300 species, spanning bacteria, yeasts, filamentous fungi, and mycobacteria MALDI Biotyper®: Early KOL access to a novel cloud‑based identification solution, enabling identification against several specialist, expert‑curated libraries MALDI Biotyper®: Ongoing broad, multi‑year clinical and translational study programs advancing automation, potential future claims, and next‑generation analytics, including: IVDR-compliant clinical validation studies evaluating automated sample preparation workflows, cove
Introductions span console electronics, quantitative NMR software, 80 MHz benchtop FT‑NMR, solid‑state and dissolution DNP, and automated protein and RNA workflows. At the Experimental Nuclear Magnetic Resonance Conference (ENC), Bruker Corporation (NASDAQ:BRKR) today announced new NMR products and workflow solutions designed to expand performance, sensitivity, and automation across research and applied NMR. The introductions span console electronics, quantitative chemistry, benchtop FT-NMR, solid-state and dissolution Dynamic Nuclear Polarization (DNP), and digital workflows that support reproducible, unattended, and data-driven automation. This press release features multimedia. View t
Live finance-specific insights
Q1 2026 revenues of $823.4 million, up 2.7% year-over-year (yoy), down 4.4% organically Q1-26 GAAP diluted earnings per share (EPS) $0.02; non-GAAP diluted EPS $0.31 Q1-26 Bruker Scientific Instruments (BSI) bookings up high-single digits % organically yoy; BSI book-to-bill ratio above 1.0x for 3rd consecutive quarter Reconfirming previous FY2026 guidance: Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2% Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind Bruker Corporation (NASDAQ:BRKR) today announced financial results for the three months ended March 31, 2026. Frank H. Laukien, Bruker's President and C
Bruker Corporation (NASDAQ:BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026. The Company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q1 2026 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-4
Q4-25 revenues of $977.2 million, flat year-over-year (yoy), down ~5% organically Q4-25 GAAP diluted earnings per share (EPS) of $0.10; non-GAAP diluted EPS of $0.59 FY25 revenues of $3.44 billion, up ~2% yoy, down ~4% organically FY25 GAAP diluted loss per share of $(0.15); non-GAAP diluted EPS of $1.83 Bruker initiates FY26 guidance: Revenues of $3.57 to $3.60 billion, up 4% to 5% yoy, with organic growth of 1% to 2% Non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy, including an ~8% FX headwind Bruker Corporation (NASDAQ:BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025. Frank H. Laukien, Bruker's Presid
Bruker Corporation (NASDAQ:BRKR, BRKRP)) today announced that its Board of Directors ("Board") has approved payment of a quarterly cash dividend in the amount of $3.9844 per share on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock Dividend"). The Mandatory Convertible Preferred Stock Dividend will be paid on March 2, 2026 to stockholders of record as of February 15, 2026. About Bruker Corporation – Leader of the Post-Genomic Era Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's hi
Bruker Corporation (NASDAQ:BRKR) today announced it will report fourth quarter and fiscal year 2025 financial results before market opening on Thursday, February 12, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q4 2025 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-43
TOFWERK is a profitable innovator in compact, ultra-fast time-of-flight (TOF) mass spectrometry for real-time air and semiconductor cleanroom monitoring, food, flavors & fragrances markets, and FIB-TOF accessories for electron microscopes The ultra-sensitive Vocus™ TOF-MS is customizable for real-time air and cleanroom monitoring applications Microwave-induced plasma (MIP)-TOF systems with atto-to-femtogram detection limits for real-time quantification of trace elements and metals Proprietary flow tube-based VUV CI sources for positive and negative trace organics, inorganics and PFAS contaminants Focused Ion Beam (FIB)-TOF accessories for scanning electron microscopes Bruker
Bruker Corporation (NASDAQ:BRKR, BRKRP)) today announced that its Board of Directors ("Board") has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock, par value $0.01 per share (the "Common Stock Dividend"). The Common Stock Dividend will be paid on January 2, 2026 to stockholders of record as of December 8, 2025. The Board also approved payment of a quarterly cash dividend in the amount of $3.6745 per share on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock Dividend"). The Mandatory Convertible Preferred Stock Dividend will be paid on Decemb
Q3 2025 revenues of $860.5 million, down 0.5% year-over-year (yoy), down 4.5% organically Q3 2025 GAAP diluted loss per share $(0.41); non-GAAP diluted earnings per share (EPS) $0.45 Updated FY2025 guidance: Revenue $3.41 to $3.44 billion; reported growth of 1-2% yoy, organic decline of 4-5% Non-GAAP EPS $1.85 to $1.90 Bruker Corporation (NASDAQ:BRKR) today announced financial results for the three and nine months ended September 30, 2025. Frank H. Laukien, Bruker's President and CEO, commented: "In the third quarter, we were encouraged by our mid-single digit percentage organic bookings growth year-over-year, with a Scientific Instruments segment book-to-bill ratio
Bruker Corporation (NASDAQ:BRKR) today announced it will report third quarter 2025 financial results before market opening on Monday, November 3, 2025. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q3 2025 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be referenced during the webcast and will be posted to the Company's website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and
Live Leadership Updates
Bruker Corporation (NASDAQ:BRKR) announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of today. Mr. Bernard is an international life-science tools and diagnostics industry executive with decades of relevant leadership, strategic and operational experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401348395/en/Thierry Bernard Frank H. Laukien, the Chairman, President and CEO of Bruker Corporation, stated: "Bruker is delighted that Thierry is joining our Board. I have admired his successful track record, astute strategic initiatives, and outstanding execution for many years,
ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with
Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic
ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens and viral disease ELITechGroup has its R&D, manufacturing and commercial focus on Europe and the Americas Bruker to acquire ELITechGroup revenues of ~Euro 150 million p.a. with >80% consumables revenue Bruker Corporation (NASDAQ:BRKR) announced today that
Chemspeed Accelerates Bruker's Laboratory Automation and Digitalization Drive Bruker Corporation (NASDAQ:BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240125759758/en/Chemspeed's modular, compact FLEX automation workstations enhance chemical and materials science R&D and lab
Bruker (NASDAQ:BRKR) today announced the acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications. Tornado, with over a decade of experience in innovative and industry-proven Raman solutions, will enhance Bruker's biopharma PAT portfolio with its well-established products. Financial details were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240104658012/en/Tornado's proprietary product, the Process Guardian™, which offers superior performance for RAMAN biopharma process applications (Photo: Busines
High-end STEM Technology Expands Bruker's Portfolio for Materials Science Research Bruker today announced that it has acquired Nion, a privately-held company that develops and manufactures innovative high-end scanning transmission electron microscopes (STEM). Nion was the first company to introduce aberration correction for STEM instruments with ultra-high stability for highest resolution images, and Nion is the world leader in ultra-high energy and spatial resolution electron energy-loss spectroscopy (EELS). This acquisition enhances Bruker's product offerings and technology portfolio in materials science research and provides the technology base for applications in electron diffraction
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005639/en/Dr. Philip Ma is Chief Executive Officer, President, and Founder of PrognomiQ (Photo: Business Wire) Dr. Ma is Chief Executive Officer, founder, and a director of PrognomiQ, a privately held healthcare company that is developing next-generation, transformative multiomics products to enable early cancer detection and cancer treatment selection and monitoring assays. Before PrognomiQ, Dr. Ma was Chief Business
This live feed shows all institutional transactions in real time.
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)